Drugs / Electrofusion DC vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00625755 | Dec 2002 → Jun 2005 | renal cell carcinoma | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Electrofusion DC vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00625755 ↗ |
| Modality | Vaccine | “Electrofusion DC vaccine” NCT00625755 ↗ |
| Route | Subcutaneous | “The thawed vaccine is administered SC into a single site every three weeks.” NCT00625755 ↗ |